India tightens stem cell therapy regulations, restricts autism treatments

India's regulatory authorities have announced stricter guidelines governing the use of stem cell therapies, with particular emphasis on preventing their unauthorized application in autism treatment. Under the new framework, stem cell interventions for autism will be permitted only within the scope of formally approved clinical trials conducted under proper medical supervision.

The ministry's directive addresses growing concerns about the proliferation of unregulated stem cell clinics offering treatments for autism and other conditions without adequate scientific evidence or regulatory oversight. By restricting therapeutic applications to controlled trial settings, the government aims to ensure that patients receive only evidence-based treatments while allowing legitimate research to proceed.

The move reflects heightened scrutiny of the stem cell therapy sector in India, where private clinics have increasingly marketed such treatments for various neurological and developmental conditions. Health officials have emphasized that stem cell therapies remain largely experimental, and their safety and efficacy for autism have not been established through rigorous clinical testing.

The restricted approach will allow researchers to continue investigating potential therapeutic applications of stem cells within approved institutional frameworks while protecting the public from unproven interventions. Patients and healthcare providers have been advised to rely on established, evidence-based treatments for autism rather than seeking stem cell therapies outside of authorized clinical research programs.